EE05261B1 - Kombineeritud kemoteraapia, milles kasutatakse (SP-4-3)-(cis-amiindikloro-[2-metlpridiin]plaatina (II) kombinatsioonis vhivastase vahendiga, mis ei p?hine plaatinal - Google Patents
Kombineeritud kemoteraapia, milles kasutatakse (SP-4-3)-(cis-amiindikloro-[2-metlpridiin]plaatina (II) kombinatsioonis vhivastase vahendiga, mis ei p?hine plaatinalInfo
- Publication number
- EE05261B1 EE05261B1 EEP200200648A EEP200200648A EE05261B1 EE 05261 B1 EE05261 B1 EE 05261B1 EE P200200648 A EEP200200648 A EE P200200648A EE P200200648 A EEP200200648 A EE P200200648A EE 05261 B1 EE05261 B1 EE 05261B1
- Authority
- EE
- Estonia
- Prior art keywords
- platinum
- combination
- methylpiperidine
- cis
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0011903.2A GB0011903D0 (en) | 2000-05-18 | 2000-05-18 | Combination chemotherapy |
PCT/GB2001/002060 WO2001087313A1 (en) | 2000-05-18 | 2001-05-10 | Combination chemotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200200648A EE200200648A (et) | 2004-06-15 |
EE05261B1 true EE05261B1 (et) | 2010-02-15 |
Family
ID=9891766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200200648A EE05261B1 (et) | 2000-05-18 | 2001-05-10 | Kombineeritud kemoteraapia, milles kasutatakse (SP-4-3)-(cis-amiindikloro-[2-metlpridiin]plaatina (II) kombinatsioonis vhivastase vahendiga, mis ei p?hine plaatinal |
Country Status (28)
Country | Link |
---|---|
US (1) | US20040053882A1 (de) |
EP (2) | EP1283712A1 (de) |
JP (2) | JP2003533485A (de) |
KR (2) | KR20090040926A (de) |
CN (3) | CN100411628C (de) |
AR (1) | AR030281A1 (de) |
AU (3) | AU2001252442B8 (de) |
BG (1) | BG66113B1 (de) |
BR (1) | BR0110837A (de) |
CA (1) | CA2410067A1 (de) |
CZ (1) | CZ20023766A3 (de) |
EE (1) | EE05261B1 (de) |
GB (1) | GB0011903D0 (de) |
HK (1) | HK1049446A1 (de) |
HU (1) | HUP0302130A3 (de) |
IL (1) | IL151959A0 (de) |
IS (1) | IS6571A (de) |
MX (1) | MXPA02011247A (de) |
MY (1) | MY138923A (de) |
NO (1) | NO332079B1 (de) |
NZ (1) | NZ521632A (de) |
PL (1) | PL357721A1 (de) |
RU (2) | RU2429838C2 (de) |
SK (1) | SK16392002A3 (de) |
TW (1) | TW200637565A (de) |
UA (1) | UA81098C2 (de) |
WO (1) | WO2001087313A1 (de) |
ZA (1) | ZA200209279B (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
WO2008109417A1 (en) * | 2007-03-02 | 2008-09-12 | Case Western Reserve University | Mgmt inhibitor combinations for the treatment of neoplastic disorders |
PT2305255E (pt) * | 2001-12-03 | 2012-09-04 | Bayer Healthcare Llc | Compostos de arilureia em combinação com outros agentes citostáticos ou citotóxicos para tratamento de cancros humanos |
WO2004087105A1 (en) * | 2003-04-02 | 2004-10-14 | Celator Pharmaceuticals, Inc. | Combination formulations of platinum agents and fluoropyrimidines |
AU2006255125B2 (en) * | 2005-06-07 | 2011-12-08 | Yale University | Methods of treating cancer and other conditions or disease states using LFMAU and LDT |
US7616481B2 (en) * | 2005-12-28 | 2009-11-10 | Sandisk Corporation | Memories with alternate sensing techniques |
CA2652926A1 (en) * | 2006-05-26 | 2007-12-06 | Bayer Healthcare Llc | Drug combinations with substituted diaryl ureas for the treatment of cancer |
US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
CN101809024A (zh) * | 2007-07-16 | 2010-08-18 | 铂雅制药公司 | 吡铂的口服制剂 |
US20110052581A1 (en) * | 2008-02-08 | 2011-03-03 | Poniard Pharmaceuticals Inc. | Use of picoplatin and cetuximab to treat colorectal cancer |
CN101302235B (zh) * | 2008-06-30 | 2011-06-01 | 昆明贵研药业有限公司 | 甲啶铂的提纯 |
US20130211384A1 (en) * | 2010-07-28 | 2013-08-15 | Fondazione Irccs Istituto Nazionale Dei Tumori | Therapeutic agent, composition including said agent, implantable device and process for the treatment of cervical cancer and/or for the prevention of the formation of neoplasms in correspondence of the cervix in a human female genital system |
KR101389072B1 (ko) * | 2011-05-25 | 2014-04-23 | 가톨릭대학교 산학협력단 | BHRF1 발현 억제를 위한 siRNA 및 이를 포함하는 조성물 |
MX2018004137A (es) * | 2015-10-05 | 2018-06-13 | NuCana plc | Terapia de combinacion. |
CN113694205B (zh) * | 2021-09-23 | 2023-05-16 | 山东第一医科大学(山东省医学科学院) | 5-ht受体抑制剂和顺铂在制备治疗肝癌的药物中的应用 |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1432562A (en) * | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum co-ordination compounds |
GB2060615B (en) * | 1979-08-23 | 1983-06-22 | Johnson Matthey Co Ltd | Platinum-amine complexes |
US4302446A (en) * | 1979-10-02 | 1981-11-24 | Bristol-Myers Company | Pharmaceutical compositions |
IL63658A0 (en) * | 1980-09-03 | 1981-11-30 | Johnson Matthey Plc | Co-ordination compound of platinum and its preparation |
US4533502A (en) * | 1983-02-22 | 1985-08-06 | Rochon Fernande D | Platinum (II) compounds and their preparation |
ATE63919T1 (de) * | 1984-06-27 | 1991-06-15 | Johnson Matthey Plc | Platinkoordinationsverbindungen. |
US5082655A (en) * | 1984-07-23 | 1992-01-21 | Zetachron, Inc. | Pharmaceutical composition for drugs subject to supercooling |
FR2586428B1 (fr) * | 1985-08-26 | 1988-11-25 | Pasteur Institut | Polypeptides et anticorps, caracteristiques du papillomavirus et leurs applications au diagnostic in vitro, a la prevention et/ou la lutte contre des infections a papillomavirus |
US4902797A (en) * | 1986-12-18 | 1990-02-20 | Shionogi & Co., Ltd. | Ammine-alicyclic amine-platinum complexes and antitumor agents |
MX9203808A (es) * | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
CN1016693B (zh) * | 1987-06-05 | 1992-05-20 | 北京工业大学 | 新顺铂铬合物的制备方法 |
GB9105037D0 (en) * | 1991-03-09 | 1991-04-24 | Johnson Matthey Plc | Improvements in chemical compounds |
US5244991A (en) * | 1991-10-15 | 1993-09-14 | Phillips Petroleum Company | Olefin polymerization process |
AU671605B2 (en) * | 1991-11-15 | 1996-09-05 | Smithkline Beecham Corporation | Combination chemotherapy |
WO1993020235A1 (en) * | 1992-04-01 | 1993-10-14 | The Johns Hopkins University School Of Medicine | Methods of detecting mammalian nucleic acids isolated from stool specimen and reagents therefor |
FR2707988B1 (fr) * | 1993-07-21 | 1995-10-13 | Pf Medicament | Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant. |
US5624919A (en) * | 1993-09-14 | 1997-04-29 | The University Of Vermont And State Agricultural College | Trans platinum (IV) complexes |
GB9408218D0 (en) * | 1994-04-26 | 1994-06-15 | Johnson Matthey Plc | Improvements in platinum complexes |
AU2768295A (en) * | 1994-07-11 | 1996-02-09 | Hoechst Marion Roussel, Inc. | Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy |
US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
CN1039813C (zh) * | 1994-10-31 | 1998-09-16 | 西安五环(集团)股份有限公司 | 具抗癌效应的顺式-二氨-1,1-环戊二羧酸根合铂(ⅱ)的化合物及其合成方法 |
US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
GB9502799D0 (en) * | 1995-02-14 | 1995-04-05 | Johnson Matthey Plc | Improvements in platinum complexes |
CN1039588C (zh) * | 1995-03-29 | 1998-08-26 | 邹娟 | 新的抗肿瘤铂络合物 |
US6245349B1 (en) * | 1996-02-23 | 2001-06-12 | éLAN CORPORATION PLC | Drug delivery compositions suitable for intravenous injection |
US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US5919815A (en) * | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
US6544961B1 (en) * | 1996-06-25 | 2003-04-08 | Smithkline Beecham Corporation | Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatments of HIV |
WO1999056742A1 (en) * | 1998-05-04 | 1999-11-11 | Auckland Uniservices Limited | Chemotherapeutic treatment |
DE19847618A1 (de) * | 1998-10-15 | 2000-04-20 | Basf Ag | Verfahren zur Herstellung von festen Dosierungsformen |
US6235782B1 (en) * | 1998-11-12 | 2001-05-22 | Rifat Pamukcu | Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
MXPA01010430A (es) * | 1999-04-13 | 2002-03-27 | Anormed Inc | Procedimiento para preparar complejos de aminoplatino. |
US6413953B1 (en) * | 1999-04-13 | 2002-07-02 | Anormed Inc. | Pt(IV) antitumor agent |
EP1224303A2 (de) * | 1999-10-18 | 2002-07-24 | Emory University | Tms1 zusammensetzungen und methoden zur verwendung |
GB9925127D0 (en) * | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
US20020102301A1 (en) * | 2000-01-13 | 2002-08-01 | Joseph Schwarz | Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof |
US6420473B1 (en) * | 2000-02-10 | 2002-07-16 | Bpsi Holdings, Inc. | Acrylic enteric coating compositions |
AR031679A1 (es) * | 2000-02-16 | 2003-10-01 | Astellas Pharma Inc | Una composicion farmaceutica |
US20030027808A1 (en) * | 2000-02-29 | 2003-02-06 | Palmer Peter Albert | Farnesyl protein transferase inhibitor combinations with platinum compounds |
US6545010B2 (en) * | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
US20020110601A1 (en) * | 2000-03-31 | 2002-08-15 | Roman Perez-Soler | Antineoplastic platinum therapeutic method and composition |
EE200200565A (et) * | 2000-03-31 | 2004-06-15 | Angiogene Pharmaceuticals Ltd. | Vaskulaarse kahjustava toimega kombinatsioonravi |
EP1319403A4 (de) * | 2000-08-11 | 2009-07-08 | Dainippon Sumitomo Pharma Co | Mittel gegen cisplatin-toleranten krebs |
US6894049B1 (en) * | 2000-10-04 | 2005-05-17 | Anormed, Inc. | Platinum complexes as antitumor agents |
US6544962B1 (en) * | 2000-11-02 | 2003-04-08 | Matrix Pharmaceutical, Inc. | Methods for treating cellular proliferative disorders |
SE0004671D0 (sv) * | 2000-12-15 | 2000-12-15 | Amarin Dev Ab | Pharmaceutical formulation |
US6673370B2 (en) * | 2001-05-15 | 2004-01-06 | Biomedicines, Inc. | Oxidized collagen formulations for use with non-compatible pharmaceutical agents |
MXPA04001071A (es) * | 2001-08-06 | 2004-05-20 | Astrazeneca Ab | Dispersion acuosa que comprende nanoparticulas estables de un activo insoluble en agua y un excipiente como trigliceridos de cadena media (mct). |
WO2003015707A2 (en) * | 2001-08-20 | 2003-02-27 | Transave, Inc. | Method for treating lung cancers |
DE10141528B4 (de) * | 2001-08-24 | 2006-08-10 | Faustus Forschungs Cie. Translational Cancer Research Gmbh | Platin(II)- und Platin(IV)-Komplexe und ihre Verwendung |
US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
US20030144312A1 (en) * | 2001-10-30 | 2003-07-31 | Schoenhard Grant L. | Inhibitors of ABC drug transporters in multidrug resistant cancer cells |
US20060078618A1 (en) * | 2001-12-11 | 2006-04-13 | Constantinides Panayiotis P | Lipid particles and suspensions and uses thereof |
AU2003220022A1 (en) * | 2002-03-01 | 2003-09-16 | Trustees Of Dartmouth College | Compositions and methods for preventing sporadic neoplasia in colon |
US20040010553A1 (en) * | 2002-07-15 | 2004-01-15 | International Business Machines Corporation | Peer to peer location based services |
WO2004006859A2 (en) * | 2002-07-16 | 2004-01-22 | Sonus Pharmaceuticals, Inc. | Platinum compound |
CN1681478A (zh) * | 2002-08-02 | 2005-10-12 | 川塞夫有限公司 | 铂聚集体及其制备方法 |
US20040156816A1 (en) * | 2002-08-06 | 2004-08-12 | David Anderson | Lipid-drug complexes in reversed liquid and liquid crystalline phases |
AU2002951833A0 (en) * | 2002-10-02 | 2002-10-24 | Novogen Research Pty Ltd | Compositions and therapeutic methods invloving platinum complexes |
TWI323662B (en) * | 2002-11-15 | 2010-04-21 | Telik Inc | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
DE10256182A1 (de) * | 2002-12-02 | 2004-06-24 | Merck Patent Gmbh | 2-Oxadiazolchromonderivate |
ATE389650T1 (de) * | 2003-04-30 | 2008-04-15 | Merck Patent Gmbh | Chromenonderivate |
US20050020556A1 (en) * | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes |
CA2566477A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
EP1758887A1 (de) * | 2004-05-14 | 2007-03-07 | Pfizer Products Incorporated | Pyrimidinderivate zur behandlung von anormalem zellwachstum |
TW200538149A (en) * | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
TW200600091A (en) * | 2004-05-21 | 2006-01-01 | Telik Inc | Sulfonylethyl phosphorodiamidates |
US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
EP2298292A3 (de) * | 2004-06-18 | 2011-08-10 | Agennix USA Inc. | Kinasehemmer zur Behandlung von Krebs |
US20060003950A1 (en) * | 2004-06-30 | 2006-01-05 | Bone Care International, Inc. | Method of treating prostatic diseases using a combination of vitamin D analogues and other agents |
US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
RU2361592C2 (ru) * | 2004-09-22 | 2009-07-20 | Пфайзер Инк. | Терапевтические комбинации, содержащие ингибитор поли(адф-рибоза)полимеразы |
US20090065522A1 (en) * | 2004-10-13 | 2009-03-12 | Nadir Benouali | Unit dose compliance monitoring and reporting device and system |
US7807662B2 (en) * | 2004-12-23 | 2010-10-05 | University Of South Florida | Platinum IV complex inhibitor |
WO2006090931A1 (ja) * | 2005-02-28 | 2006-08-31 | Eisai R & D Management Co., Ltd. | スルホンアミド化合物の抗癌剤との新規併用 |
WO2006104668A2 (en) * | 2005-03-11 | 2006-10-05 | Temple University - Of The Commonwealth System Of Higher Education | Composition and methods for the treatment of proliferative diseases |
PT1888550E (pt) * | 2005-05-12 | 2014-09-03 | Abbvie Bahamas Ltd | Promotores de apoptose |
NZ592132A (en) * | 2005-08-31 | 2012-12-21 | Abraxis Bioscience Llc | Composition comprising nanoparticles of docitaxel and a citrate |
WO2007056236A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with lipid-based platinum compound formulations administered intravenously |
US20070190180A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously |
US20070190182A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
US20070122350A1 (en) * | 2005-11-30 | 2007-05-31 | Transave, Inc. | Safe and effective methods of administering therapeutic agents |
US8143236B2 (en) * | 2005-12-13 | 2012-03-27 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods |
EP2502628B1 (de) * | 2006-06-23 | 2016-12-14 | Alethia Biotherapeutics Inc. | An Krebs beteiligte Polynukleotid- und Polypeptidsequenzen |
US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
CA2677639A1 (en) * | 2007-02-09 | 2008-08-14 | Poniard Pharmaceuticals, Inc. | Encapsulated picoplatin |
WO2008150506A1 (en) * | 2007-05-31 | 2008-12-11 | Ascenta Therapeutics, Inc. | Pulsatile dosing of gossypol for treatment of disease |
TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
HUE035101T2 (hu) * | 2007-09-28 | 2018-05-02 | Pfizer | Ráksejtek célzása nanorészecskék alkalmazásával |
US20110052581A1 (en) * | 2008-02-08 | 2011-03-03 | Poniard Pharmaceuticals Inc. | Use of picoplatin and cetuximab to treat colorectal cancer |
-
2000
- 2000-05-18 GB GBGB0011903.2A patent/GB0011903D0/en not_active Ceased
-
2001
- 2001-05-09 MY MYPI20012142A patent/MY138923A/en unknown
- 2001-05-10 IL IL15195901A patent/IL151959A0/xx unknown
- 2001-05-10 AU AU2001252442A patent/AU2001252442B8/en not_active Ceased
- 2001-05-10 KR KR1020097006728A patent/KR20090040926A/ko active Search and Examination
- 2001-05-10 HU HU0302130A patent/HUP0302130A3/hu unknown
- 2001-05-10 PL PL01357721A patent/PL357721A1/xx not_active IP Right Cessation
- 2001-05-10 CN CNB01809337XA patent/CN100411628C/zh not_active Expired - Fee Related
- 2001-05-10 BR BR0110837-9A patent/BR0110837A/pt not_active Application Discontinuation
- 2001-05-10 EP EP01925764A patent/EP1283712A1/de not_active Ceased
- 2001-05-10 SK SK1639-2002A patent/SK16392002A3/sk not_active Application Discontinuation
- 2001-05-10 CN CNA200810110276XA patent/CN101310719A/zh active Pending
- 2001-05-10 EP EP04078357A patent/EP1530969A1/de not_active Ceased
- 2001-05-10 MX MXPA02011247A patent/MXPA02011247A/es active IP Right Grant
- 2001-05-10 CA CA002410067A patent/CA2410067A1/en not_active Abandoned
- 2001-05-10 WO PCT/GB2001/002060 patent/WO2001087313A1/en active IP Right Grant
- 2001-05-10 NZ NZ521632A patent/NZ521632A/en not_active IP Right Cessation
- 2001-05-10 AR ARP010102214A patent/AR030281A1/es unknown
- 2001-05-10 US US10/276,503 patent/US20040053882A1/en not_active Abandoned
- 2001-05-10 AU AU5244201A patent/AU5244201A/xx active Pending
- 2001-05-10 EE EEP200200648A patent/EE05261B1/xx not_active IP Right Cessation
- 2001-05-10 JP JP2001583780A patent/JP2003533485A/ja active Pending
- 2001-05-10 KR KR1020027015404A patent/KR20030014228A/ko not_active Application Discontinuation
- 2001-05-10 CZ CZ20023766A patent/CZ20023766A3/cs unknown
- 2001-05-10 CN CNA2007101119747A patent/CN101084886A/zh active Pending
- 2001-05-21 TW TW095125500A patent/TW200637565A/zh unknown
- 2001-10-05 UA UA20021210043A patent/UA81098C2/uk unknown
-
2002
- 2002-09-27 IS IS6571A patent/IS6571A/is unknown
- 2002-11-14 ZA ZA200209279A patent/ZA200209279B/en unknown
- 2002-11-15 NO NO20025502A patent/NO332079B1/no not_active IP Right Cessation
- 2002-11-15 BG BG107281A patent/BG66113B1/bg unknown
-
2003
- 2003-03-05 HK HK03101630.1A patent/HK1049446A1/zh unknown
-
2006
- 2006-03-09 AU AU2006201008A patent/AU2006201008C1/en not_active Ceased
- 2006-06-22 RU RU2006122350/15A patent/RU2429838C2/ru not_active IP Right Cessation
-
2010
- 2010-05-04 RU RU2010117635/15A patent/RU2587013C2/ru not_active IP Right Cessation
-
2011
- 2011-12-26 JP JP2011283923A patent/JP2012062329A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE05261B1 (et) | Kombineeritud kemoteraapia, milles kasutatakse (SP-4-3)-(cis-amiindikloro-[2-metlpridiin]plaatina (II) kombinatsioonis vhivastase vahendiga, mis ei p?hine plaatinal | |
FI964732A (fi) | Kahden SIM-kortin käyttäminen samalla MSISDN-numerolla | |
BR9814996B1 (pt) | sistema telefânico celular, e, processo para uso em um sistema telefânico celular para atribuiÇço de canais de trÁfego. | |
BR9915457B1 (pt) | composições de moldagem, uso e artigo. | |
MXPA03004116A (es) | Copolimero de bloque, composicion del mismo, y pelicula obtenida del mismo. | |
DE59808105D1 (de) | Bausteinsystem, insbesondere spielbausteinsystem | |
DK1950302T3 (da) | Streptokok-antigener. | |
FI20002274A (fi) | Nopeakäynnisteinen suuritarkkuuksinen GPS-vastaanotin | |
DE69942024D1 (de) | Selektivruf-funkgerät mit klapptastatur | |
IS5888A (is) | Efnameðferð við krabbameini með asetýldínalíni blönduðu gemsítabíni, kapesítabíni eða sisplatíni | |
DE50012004D1 (de) | Gerät, insbesondere Fahrzeug | |
MA26768A1 (fr) | Combinaison de chimiotherapie | |
DE60104144D1 (de) | Zellularkanalzuweisung mit mehrbenutzerdetektion | |
IT1304443B1 (it) | Dispositivo formatore di gruppi di sigarette. | |
DE69932020D1 (de) | Kanalvergabe in mobilfunksystemen | |
IT1315991B1 (it) | Proiettore di veicolo con dispositivo di occultamento mobile. | |
BR9908575B1 (pt) | composição gelificada com base em sabão. | |
ITTO20000811A0 (it) | Dispositivo di schiumatura. | |
DE69900573D1 (de) | N,N-Dialkylanilinazo-Farbstofflösungen | |
ES1043315Y (es) | Dispositivo de faro. | |
IT1303717B1 (it) | Dispositivo di illuminazione, in particolare per veicoli. | |
ES1041836Y (es) | Perfeccionamientos en dispositivos de señalizacion para gradas, peldaños y similares. | |
ES1041927Y (es) | Tija para sillin amortiguadora, regulable y girable. | |
DE59203751D1 (de) | Abstützvorrichtung für Sonderfahrzeuge, insbesondere für fahrbare Betonpumpen. | |
IT246104Y1 (it) | Segnalatore moblile per uso automobilistico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |
|
MM4A | Lapsed by not paying the annual fees |
Effective date: 20140510 |